Literature DB >> 33761123

HMGB-1 and TGFβ-1 highlight immuno-inflammatory and fibrotic processes before proteinuria onset in pediatric patients with Alport syndrome.

R Chimenz1, V Chirico2, P Basile2, A Carcione2, G Conti2, P Monardo3, A Lacquaniti3.   

Abstract

INTRODUCTION: Alport syndrome (ALP) is a rare genetic condition characterized by progressive involvement of the basal membranes and renal dysfunction. The purpose of the study was to evaluate urinary (u) and serum (s) levels of tumor growth factor (TGF)-beta(β) and high mobility group box (HMGB)-1 in ALP patients with normal renal function, albuminuria and proteinuria.
METHODS: A prospective, single-center study was performed with a follow-up period of 12 months, enrolling 11 pediatric ALP patients and 10 healthy subjects (HS). Normal values of serum creatinine, albuminuria and proteinuria, as well as unaltered estimated glomerular filtration rate (eGFR) were required at enrollment.
RESULTS: ALP patients had significantly higher levels of serum and urinary HMGB1 compared to HS. The same trend was observed for TGF-β1, with higher values in ALP patients than in HS. HMGB1 and TGF-β1 correlated with each other and with markers of renal function and damage. Urinary biomarkers did not correlate with eGFR, whereas sHMGB1 and sTGF-β1 were negatively related to filtration rate (r: - 0.66; p = 0.02, r: - 0.96; p < 0.0001, respectively). Using proteinuria as a dependent variable in a multiple regression model, only the association with sTGF-β1 (β = 0.91, p < 0.0001) remained significant.
CONCLUSIONS: High levels of HMGB1 and TGF-β1 characterized ALP patients with normal renal function, highlighting the subclinical pro-fibrotic and inflammatory mechanisms triggered before the onset of proteinuria. Further studies are needed to evaluate the role of HMGB1 and TGFβ-1 in ALP patients.
© 2021. Italian Society of Nephrology.

Entities:  

Keywords:  Alport syndrome; HMGB-1; Proteinuria; Renal biomarker; Renal fibrosis; TGF-β1

Mesh:

Substances:

Year:  2021        PMID: 33761123     DOI: 10.1007/s40620-021-01015-z

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  3 in total

1.  Introduction to the special issue: "Focus on pediatric nephrology".

Authors:  R Chimenz
Journal:  J Biol Regul Homeost Agents       Date:  2019 Sep-Oct       Impact factor: 1.711

2.  Alport's syndrome.

Authors:  V Bruni; M Petrisano; F Tarsitano; F Falvo; F Parisi; U Cucinotta; P Betta; V Di Benedetto; M G Scuderi; L Pensabene; S Sestito; C Cuppari; C Fede; R Chimenz; D Concolino
Journal:  J Biol Regul Homeost Agents       Date:  2019 Sep-Oct       Impact factor: 1.711

3.  Establishment of microRNA, transcript and protein regulatory networks in Alport syndrome induced pluripotent stem cells.

Authors:  Wenbiao Chen; Donge Tang; Yong Dai; Hongyan Diao
Journal:  Mol Med Rep       Date:  2018-11-20       Impact factor: 2.952

  3 in total
  4 in total

1.  Pulsed Electromagnetic Field (PEMF) Treatment Reduces Lipopolysaccharide-Induced Septic Shock in Mice.

Authors:  Chang-Gun Lee; Chanoh Park; Soonjae Hwang; Ju-Eun Hong; Minjeong Jo; Minseob Eom; Yongheum Lee; Ki-Jong Rhee
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

Review 2.  Molecular and Cellular Mechanisms Underlying the Initiation and Progression of Alport Glomerular Pathology.

Authors:  Dominic Cosgrove; Jacob Madison
Journal:  Front Med (Lausanne)       Date:  2022-02-09

Review 3.  Potential Renal Damage Biomarkers in Alport Syndrome-A Review of the Literature.

Authors:  Ana Marta Gomes; Daniela Lopes; Clara Almeida; Sofia Santos; Jorge Malheiro; Irina Lousa; Alberto Caldas Afonso; Idalina Beirão
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

4.  Prognostic Value of Systemic Immune-Inflammation Index among Critically Ill Patients with Acute Kidney Injury: A Retrospective Cohort Study.

Authors:  Lan Jia; Chen Li; Xueqing Bi; Fang Wei; Jia Meng; Guijiang Sun; Haibo Yu; Hongye Dong; Bo Li; Yueqi Cao; Lihua Wang; Aili Jiang
Journal:  J Clin Med       Date:  2022-07-08       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.